mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression

被引：13

作者：

Guo, F. ^{[1
]}

Li, J. ^{[1
]}

Zhang, S. ^{[1
]}

Du, W. ^{[1
]}

Amarachintha, S. ^{[1
]}

Sipple, J. ^{[1
]}

Phelan, J. ^{[2
]}

Grimes, H. L. ^{[2
]}

Zheng, Y. ^{[1
]}

Pang, Q. ^{[1
]}

机构：

[1] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA

[2] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA

来源：

关键词：

MAMMALIAN TARGET; RAPAMYCIN; PATHWAY; CANCER;

D O I：

10.1038/leu.2013.215

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：203 / 206

页数：4

共 15 条

[11] The multifaceted role of mTOR in cellular stress responses
Proud, CG
[J]. DNA REPAIR, 2004, 3 (8-9) : 927 - 934
[12] Antileukemic activity of rapamycin in acute myeloid leukemia
Récher, C
Beyne-Rauzy, O
Demur, C
Chicanne, G
Dos Santos, C
Mansat-De Mas, V
Benzaquen, D
Laurent, G
Huguet, F
Payrastre, B
[J]. BLOOD, 2005, 105 (06) : 2527 - 2534
[13] Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis
Seif, Alix E.
[J]. CANCER GENETICS, 2011, 204 (05) : 227 - 244
[14] mTOR regulates cell survival after etoposide treatment in primary AML cells
Xu, Q
Thompson, JE
Carroll, M
[J]. BLOOD, 2005, 106 (13) : 4261 - 4268
[15] Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
Yu, Ker
Toral-Barza, Lourdes
Shi, Celine
Zhang, Wei-Guo
Lucas, Judy
Shor, Boris
Kim, Jamie
Verheijen, Jeroen
Curran, Kevin
Malwitz, David J.
Cole, Derek C.
Ellingboe, John
Ayral-Kaloustian, Semiramis
Mansour, Tarek S.
Gibbons, James J.
Abraham, Robert T.
Nowak, Pawel
Zask, Arie
[J]. CANCER RESEARCH, 2009, 69 (15) : 6232 - 6240